• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket

    6/6/23 8:36:13 AM ET
    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Industrial Machinery/Components
    Technology
    Metal Fabrications
    Industrials
    Get the next $ACMR alert in real time by email

    Gainers

    • Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) shares rose 85.8% to $0.7985 in pre-market trading.
    • Chijet Motor Company, Inc. (NASDAQ:TTOO) shares surged 51.3% to $0.1060 in pre-market trading after dipping around 31% on Monday. T2 Biosystems reported submission for the FDA breakthrough device designation for candida auris diagnostic test.
    • Secoo Holding Limited (NASDAQ:SECO) gained 35.8% to $1.100 in pre-market trading.
    • Zura Bio Limited (NASDAQ:ZURA) shares gained 35.4% to $8.79 in pre-market trading after the company completed approximately $80 million financing with the focus on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist.
    • Greenlane Holdings, Inc. (NASDAQ:GNLN) gained 29.5% to $0.36 in pre-market trading. Greenlane reported effectiveness of previously announced reverse stock split.
    • GitLab Inc. (NASDAQ:GTLB) shares rose 27.6% to $45.18 in pre-market trading following better-than-expected first-quarter results.
    • Regional Health Properties, Inc. (NYSE:RHE) shares climbed 25.8% to $3.78 in pre-market trading after gaining around 4% on Monday.
    • Mereo BioPharma Group plc - ADR (NASDAQ:MREO) rose 16.2% to $1.22 in pre-market trading. Ultragenyx and Mereo BioPharma reported data from ongoing Phase 2/3 Orbit study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI).
    • Bioventus Inc. (NASDAQ:BVS) rose 16% to $3.13 in pre-market trading after declining around 9% on Monday.
    • Coya Therapeutics, Inc. (NASDAQ:COYA) shares gained 13.5% to $4.77 in pre-market trading after declining 8% on Monday.

    Losers

    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) fell 39.6% to $1.01 in pre-market after dropping over 20% on Monday.
    • Pasithea Therapeutics Corp (NASDAQ:KTTA) shares dropped 35% to $0.33 in pre-market trading. Pasithea Therapeutics shares jumped 25% on Monday after Lucy Scientific Discovery proposed to acquire the company for $0.60 per share in cash and $0.25 per share in Lucy stock.
    • Sono Group N.V. (NASDAQ:SEV) fell 15.7% to $0.2569 in pre-market trading after gaining around 76% on Monday.
    • View, Inc. (NASDAQ:VIEW) fell 13.5% to $0.1685 in pre-market trading. View announced plans for reverse stock split to ensure full compliance with Nasdaq listing rules.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) fell 12.2% to $0.2002 in pre-market trading. Bluejay Diagnostics filed for mixed shelf of up to $25 million.
    • Ucommune International Ltd (NASDAQ:UK) shares dropped 11.5% to $0.8935 in pre-market trading after surging over 50% on Monday.
    • AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) fell 10.6% to $0.17 in pre-market trading after dropping 44% on Monday.
    • Ayro, Inc. (NASDAQ:AYRO) shares fell 10% to $0.50 in pre-market trading. AYRO, last month, reported a first-quarter sales decline of 89% Y/Y to $0.113 million, missing the consensus of $0.300 million.
    • ACM Research, Inc. (NASDAQ:ACMR) fell 8.5% to $8.90 in pre-market trading.
    • Timber Pharmaceuticals, Inc. (NYSE:TMBR) fell 8.5% to $1.72 in pre-market trading. Timber Pharmaceuticals shares jumped 26% on Monday following a positive decision from the FDA for its TMB-001 treatment.

     

    Now Read This: Dow Drops 200 Points But Investor Sentiment Improves

    Get the next $ACMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACMR
    $AGRI
    $AYRO
    $BJDX

    CompanyDatePrice TargetRatingAnalyst
    Bioventus Inc.
    $BVS
    2/9/2026$13.00Outperform
    Barrington Research
    Zura Bio Limited
    $ZURA
    2/9/2026$15.00Outperform
    Wedbush
    GitLab Inc.
    $GTLB
    1/12/2026$34.00Equal Weight → Underweight
    Barclays
    GitLab Inc.
    $GTLB
    1/12/2026$42.00Overweight → Equal-Weight
    Morgan Stanley
    GitLab Inc.
    $GTLB
    1/7/2026$40.00Overweight → Neutral
    Cantor Fitzgerald
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    GitLab Inc.
    $GTLB
    12/17/2025$52.00Buy
    BTIG Research
    GitLab Inc.
    $GTLB
    12/16/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & CFO Singleton Mark Leonard converted options into 20,153 shares and covered exercise/tax liability with 9,429 shares, increasing direct ownership by 8% to 151,812 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    2/18/26 6:30:05 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SVP & Chief Compliance Officer Church Katrina J covered exercise/tax liability with 2,133 shares and converted options into 4,375 shares, increasing direct ownership by 4% to 57,799 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    2/18/26 6:29:29 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SVP & General Counsel D'Adamio Anthony covered exercise/tax liability with 6,327 shares and converted options into 12,980 shares, increasing direct ownership by 5% to 138,069 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    2/18/26 6:28:48 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barrington Research initiated coverage on Bioventus with a new price target

    Barrington Research initiated coverage of Bioventus with a rating of Outperform and set a new price target of $13.00

    2/9/26 8:08:39 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Wedbush initiated coverage on Zura Bio Limited with a new price target

    Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    2/9/26 6:54:14 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GitLab downgraded by Barclays with a new price target

    Barclays downgraded GitLab from Equal Weight to Underweight and set a new price target of $34.00

    1/12/26 8:05:47 AM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    SEC Filings

    View All

    Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zura Bio Ltd (0001855644) (Filer)

    2/23/26 6:40:35 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pasithea Therapeutics Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

    2/20/26 5:00:53 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    2/20/26 9:54:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

    ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share. The Company notes that several recent Schedule 13G filings made by investors

    2/20/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    GitLab Chief Executive Officer Bill Staples and GitLab Chief Financial Officer Jessica Ross to Present at the Morgan Stanley Technology, Media & Telecom Conference

    All Remote - GitLab Inc., (NASDAQ:GTLB), the intelligent orchestration platform for DevSecOps, today announced that GitLab Chief Executive Officer Bill Staples and GitLab Chief Financial Officer Jessica Ross will present at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco, Calif., on Thursday, March 5, 2026. The fireside chat is scheduled for 9:15 a.m. Pacific Time and will be webcast live at the following link: cc.webcasts.com/morg007/030226a_js/?entity=40_U5OP88G A link to the webcast and replay of the fireside chat will be available on the investor relations section of the GitLab website for one year. About GitLab GitLab is the intelligent orchestration

    2/19/26 4:05:00 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Staples William bought $124,750 worth of shares (3,276 units at $38.08), increasing direct ownership by 0.96% to 345,671 units (SEC Form 4)

    4 - Gitlab Inc. (0001653482) (Issuer)

    1/5/26 6:26:25 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:56:56 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Leadership Updates

    Live Leadership Updates

    View All

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Greenlane Appoints Jason Hitchcock as Chief Executive Officer to Advance Digital Asset Treasury Strategy

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN) today announced the appointment of Jason Hitchcock as its Chief Executive Officer, effective immediately. Mr. Hitchcock is a technology executive with over 15 years of experience building and scaling revenue engines across SaaS, blockchain infrastructure, and decentralized finance. He joins Greenlane as the Company continues to execute its Berachain-focused Digital Asset Treasury ("DAT") strategy, combining disciplined capital allocation with active ecosystem participation through validator operations, staking, and liquidity provisioning. Technology Leadership and Ent

    2/18/26 8:00:00 AM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

    1/21/26 8:50:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Financials

    Live finance-specific insights

    View All

    GitLab to Announce Fourth Quarter and Full Fiscal 2026 Financial Results

    All Remote - GitLab Inc., (NASDAQ:GTLB), the intelligent orchestration platform for DevSecOps, today announced that it will report its financial results for the fourth quarter and its full fiscal year 2026, which ended January 31, 2026, after U.S. markets close on Tuesday, March 3, 2026. Management will host a conference call and webcast on the same day to discuss the company's financial results at 4:30 p.m. ET / 1:30 p.m. PT. GitLab Fourth Quarter and Full Fiscal 2026 Financial Results Conference Call and Webcast When: Tuesday, March 3, 2026 Time: 4:30 p.m. ET / 1:30 p.m. PT Earnings Call Registration Replay: A webcast replay of the conference call will be available on the invest

    2/17/26 4:05:00 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    ACM Research to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

    FREMONT, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR) announced today that it will release its financial results for the fourth quarter and fiscal year 2025 before the U.S. market open on Thursday, February 26, 2026. ACM will conduct a corresponding conference call at 8:00 a.m. U.S. Eastern Time (9:00 p.m. China Time) to discuss the results. What:ACM Fourth Quarter and Fiscal Year (ended December 31, 2025) Earnings CallWhen:8:00 a.m. U.S. Eastern Time on Thursday, February 26, 2026Webcast:ir.acmr.com/news-events/events   To join the conference call via telephone, participants must use the following link to complete an online registration process. Upon

    2/9/26 4:05:00 PM ET
    $ACMR
    Industrial Machinery/Components
    Technology

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:06:21 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care